Know Cancer

or
forgot password

Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol


N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol


Inclusion Criteria:



- subjects ages 18 and above ICF obtain

Exclusion Criteria:

- none

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Number of Participants with a significant cancer fingerprint as measured by NovellusDX Cancer Early Detection test

Outcome Description:

NovellusDX Cancer Early Detection test will identify participants with significant cancer fingerprint based on tumor protein secretion to the blood circulation in sick subjects.

Outcome Time Frame:

3.5 years

Safety Issue:

No

Principal Investigator

Yishai Ofran, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rambam MC. Haematology Department

Authority:

Israel: Ministry of Health

Study ID:

RAM-NOVEL-211-2012

NCT ID:

NCT01883388

Start Date:

June 2013

Completion Date:

Related Keywords:

  • Lung Cancer
  • Lung Cancer
  • blood sample
  • Lung Neoplasms

Name

Location